Before the 1990s, colorectal liver metastases were considered a terminal diagnosis. Adam and colleagues at Paul Brousse Hospital demonstrated that chemotherapy could convert initially unresectable colorectal liver metastases to resectable disease. In their landmark 2004 series of 1,439 consecutive patients with CRLM, 1,104 (77%) were initially unresectable. After systemic chemotherapy, 138 (12.5%) achieved sufficient response to undergo secondary hepatic resection, establishing the concept of conversion therapy as a paradigm shift in management.

Adam Conversion Series2004Landmark

12.5% conversion rate from unresectable to resectable; 5-year survival in resected patients comparable to primarily resectable disease

Ann SurgProspective CohortN=1,439

Proof

Landmark RCTs and pivotal trials that established the evidence base

The concept of two-stage hepatectomy and portal vein embolization expanded the pool of resectable patients. Multiple institutional series demonstrated that combining chemotherapy with volumetric augmentation techniques allowed curative-intent surgery for patients with bilobar disease or insufficient future liver remnant. Five-year survival rates of 30-40% after complete resection of CRLM became consistently reproducible across high-volume centers, fundamentally changing the prognosis for stage IV colorectal cancer.

Nordlinger LiverMetSurvey2013Landmark

Progression-free survival — perioperative chemotherapy HR 0.77 (95% CI 0.60-1.00, p=0.041)

Lancet OncolRCTN=364

Extension

Follow-up studies, subgroup analyses, and real-world validation

The ALPPS procedure (Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy), first described by Schnitzbauer in 2012, represented a bold extension by inducing rapid hypertrophy of the future liver remnant (74% increase in 9 days) to enable resection of otherwise unresectable disease. However, the initial enthusiasm was tempered by high morbidity and a 12% in-hospital mortality in the first 25 cases. Subsequent registry data and refined patient selection reduced complications, though ALPPS remains reserved for carefully selected cases at experienced centers.

ALPPS Original Series2012Landmark

FLR hypertrophy 74% at median 9 days; 100% stage-2 resectability; 12% in-hospital mortality

Ann SurgProspective CohortN=25

Guidelines

Integration into clinical practice guidelines and recommendations

NCCN and ESMO guidelines recommend that all patients with CRLM be evaluated by a multidisciplinary team including hepatobiliary surgeons, as resection provides the only potential for cure. Perioperative chemotherapy is standard for initially resectable disease, and conversion chemotherapy is recommended for borderline or initially unresectable cases.

NCCN

Multidisciplinary evaluation for all CRLM; resection preferred for potentially curable disease; perioperative chemotherapy recommended

ESMO

Complete resection of CRLM remains the standard of care with curative intent; conversion chemotherapy for initially unresectable disease

Now

Current standard of care and ongoing research directions

Liver resection for CRLM is established as the cornerstone of potentially curative treatment for stage IV colorectal cancer, with 5-year survival rates of 40-50% at high-volume centers. Current frontiers include liver transplantation for unresectable CRLM (supported by emerging evidence from the TRANSMET trial), integration of immunotherapy, thermal ablation for small lesions (COLLISION trial), and parenchyma-sparing approaches to maximize future options for recurrent disease.

Landmark Trials in This Story

Adam Conversion Series2004Landmark

Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival

12.5% conversion rate from unresectable to resectable; 5-year survival in resected patients comparable to primarily resectable disease

Ann SurgProspective CohortN=1,439

Nordlinger LiverMetSurvey2013Landmark

Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial

Progression-free survival — perioperative chemotherapy HR 0.77 (95% CI 0.60-1.00, p=0.041)

Lancet OncolRCTN=364

ALPPS Original Series2012Landmark

Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings

FLR hypertrophy 74% at median 9 days; 100% stage-2 resectability; 12% in-hospital mortality

Ann SurgProspective CohortN=25

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3M+ peer-reviewed articles.

Ask about this topic Try AttendMe Free

Related Evidence

Hepatobiliary Surgery

Portal Vein Embolization and ALPPS

Growing the future liver remnant

Colorectal Surgery

Laparoscopic vs Open Colorectal Cancer Surgery

Equivalent oncologic outcomes

Urology

Prostate Cancer Active Surveillance

Watching wisely

Frequently Asked Questions

What percentage of patients with colorectal liver metastases can be cured with surgery?+

Among patients who undergo complete resection of CRLM, 5-year survival rates of 40-50% are consistently achieved at high-volume centers. Even initially unresectable patients can be converted to resectability with systemic chemotherapy — Adam et al. showed a 12.5% conversion rate among 1,104 initially unresectable patients, with long-term survival comparable to primarily resectable disease.

What is ALPPS and when is it used?+

ALPPS (Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy) is a two-stage procedure that induces rapid hypertrophy of the future liver remnant (74% volume increase in ~9 days). It is reserved for patients with extensive bilobar disease where the future liver remnant is too small for safe single-stage resection. Initial reports showed high morbidity (12% mortality), and the procedure is now performed at experienced centers with refined patient selection.